Replies to post #3298 on Statera BioPharma Inc (STAB)

[ssc]

About this latest deal:

Statera entered into a non-binding term sheet with respect to a strategic agreement with Immune Therapeutics, Inc. (OTC-PINK: IMUN), a drug development and commercialization company, to sell Statera's rights to naltrexone and met-enkephalin. The transaction is contingent upon negotiation of a definitive agreement and satisfaction of a number of closing conditions, including a contingency on Immune Therapeutics financing.